Literature DB >> 22949727

Gout and its comorbidities: implications for therapy.

Lisa K Stamp1, Peter T Chapman.   

Abstract

Gout is a common form of arthritis. It is associated with a number of comorbidities, including hypertension, cardiovascular disease, renal impairment, diabetes, obesity, hyperlipidaemia and frequently in a combination known as the metabolic syndrome. These comorbidities and their treatment may have an effect on the development of gout and on the choice of therapeutic agent. Treatment of acute gout with short-term corticosteroids may be a safer option than either NSAIDs or colchicine in patients with significant renal and/or cardiac impairment. Sustained reduction of serum urate <0.36 mmol/l is required for long-term management of gout. The optimal dosing regimen for patients with renal impairment is the subject of on-going investigation. There is less experience with newer urate-lowering therapies. This review will consider the relationship between comorbidities and gout with a particular focus on the treatment of gout and the potential interactions between drugs used for gout and those for comorbid conditions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22949727     DOI: 10.1093/rheumatology/kes211

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  24 in total

1.  As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.

Authors:  A-K Tausche; M Christoph; M Forkmann; U Richter; S Kopprasch; C Bielitz; M Aringer; C Wunderlich
Journal:  Rheumatol Int       Date:  2013-09-12       Impact factor: 2.631

2.  Genetic variations in the CLNK gene and ZNF518B gene are associated with gout in case-control sample sets.

Authors:  Tian-Bo Jin; Yongchao Ren; Xugang Shi; Mutu Jiri; Na He; Tian Feng; Dongya Yuan; Longli Kang
Journal:  Rheumatol Int       Date:  2015-01-17       Impact factor: 2.631

Review 3.  Optimizing current treatment of gout.

Authors:  Frances Rees; Michelle Hui; Michael Doherty
Journal:  Nat Rev Rheumatol       Date:  2014-03-11       Impact factor: 20.543

4.  Major Cardiovascular Events in Patients with Gout and Associated Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating a Xanthine Oxidase Inhibitor.

Authors:  JoAnne Foody; Robin S Turpin; Beni A Tidwell; Debra Lawrence; Kathy L Schulman
Journal:  Am Health Drug Benefits       Date:  2017-11

5.  Comparison of new-onset gout in adults prescribed chlorthalidone vs. hydrochlorothiazide for hypertension.

Authors:  Liza Wilson; Kavita V Nair; Joseph J Saseen
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-09-25       Impact factor: 3.738

6.  Prevention of comorbidity and acute attack of gout by uric acid lowering therapy.

Authors:  Kowoon Joo; Seong-Ryul Kwon; Mie-Jin Lim; Kyong-Hee Jung; Hoyeon Joo; Won Park
Journal:  J Korean Med Sci       Date:  2014-04-25       Impact factor: 2.153

Review 7.  Drug induced exfoliative dermatitis: state of the art.

Authors:  Mona-Rita Yacoub; Alvise Berti; Corrado Campochiaro; Enrico Tombetti; Giuseppe Alvise Ramirez; Andrea Nico; Elisabetta Di Leo; Paola Fantini; Maria Grazia Sabbadini; Eustachio Nettis; Giselda Colombo
Journal:  Clin Mol Allergy       Date:  2016-08-22

8.  Risk of infections in patients with gout: a population-based cohort study.

Authors:  B Spaetgens; F de Vries; J H M Driessen; H G Leufkens; P C Souverein; A Boonen; J W M van der Meer; L A B Joosten
Journal:  Sci Rep       Date:  2017-05-03       Impact factor: 4.379

9.  Asymptomatic hyperuricemia is independently associated with coronary artery calcification in the absence of overt coronary artery disease: A single-center cross-sectional study.

Authors:  Hyunwook Kim; Seok-Hyung Kim; Ah Ran Choi; Seungkyu Kim; Hoon Young Choi; Hyung Jong Kim; Hyeong-Cheon Park
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

10.  Improvement in the management of gout is vital and overdue: an audit from a UK primary care medical practice.

Authors:  Elizabeth Cottrell; Valerie Crabtree; John J Edwards; Edward Roddy
Journal:  BMC Fam Pract       Date:  2013-11-14       Impact factor: 2.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.